Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.5466
-0.0098-1.76%
Pre-market: 0.56490.0183+3.35%08:07 EDT
Volume:4.57M
Turnover:2.47M
Market Cap:159.62M
PE:-2.74
High:0.5700
Open:0.5670
Low:0.5170
Close:0.5564
Loading ...

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
04 Dec 2024

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
03 Dec 2024

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
30 Nov 2024

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
28 Nov 2024

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

GlobeNewswire
·
27 Nov 2024

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
26 Nov 2024

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
23 Nov 2024

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
21 Nov 2024

Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies

MT Newswires Live
·
20 Nov 2024

Ocugen announces EMA granted orphan medicinal product designation for OCU410ST

TIPRANKS
·
20 Nov 2024

BRIEF-Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation For Modifier Gene Therapy Candidate Ocu410st

Reuters
·
20 Nov 2024

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410st for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease

THOMSON REUTERS
·
20 Nov 2024

Ocugen Inc - to Pursue Accelerated Marketing Authorization Application for Ocu410st

THOMSON REUTERS
·
20 Nov 2024

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

GlobeNewswire
·
20 Nov 2024

Ocugen reports positive data for OCU400, OCU410

seekingalpha
·
19 Nov 2024

BRIEF-Ocugen Announces Compelling Preliminary Data For Ocu410—A

Reuters
·
19 Nov 2024